NFKB1 and atherosclerosis: Low-dose FK506 (∼0.2 ng/mL) inhibited collar-induced atherosclerosis progression and promoted plaque stability in ApoE−/− mice, whereas higher doses similar to those given to transplant patients engaged instead NF-κB in macrophages and consequently increased production of cytokines.